Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia
Journal
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
Journal Volume
18
Journal Issue
4
Pages
436
Date Issued
2023-04-12
Author(s)
Mitsudomi, Tetsuya
Tan, Daniel
Ahn, Myung-Ju
Batra, Ullas
Cho, Byoung-Chul
Cornelio, Gerardo
Lim, Tony
Mok, Tony
Prabhash, Kumar
Reungwetwattana, Thanyanan
Ren, Sheng-Xiang
Singh, Navneet
Toyooka, Shinichi
Wu, Yi-Long
Yatabe, Yasushi
Abstract
Most published guidelines for genomic biomarker testing in NSCLC reflect the disease epidemiology and treatments readily available in Europe and North America. Nevertheless, 60% of annual global NSCLC cases occur in Asia, where patient characteristics, tumor molecular profiles, and treatments vary greatly from the Western world. For example, mutations in the EGFR occur at a higher prevalence in Asia than in other world regions. Although medical associations such as the International Association for the Study of Lung Cancer, European Society for Medical Oncology, and American Society of Clinical Oncology have described principles for tumor genomic biomarker testing in NSCLC, there is a need for recommendations specific for Asia.
Subjects
Adenocarcinoma; Biomarkers; Liquid biopsy; Non–small cell lung cancer; Squamous carcinoma; ctDNA
SDGs
Type
journal article